RxDoctor Payments Data

Steven Wisniewski

Internal Medicine · Gaylord, MINPI 1104851658

Payments from drug & device makers

$2,171in general payments, 2019–2025

Across 131 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$342
  • Boehringer Ingelheim$281
  • Pfizer$272
  • AstraZeneca$189
  • Novo Nordisk$185
  • Novartis$153
  • plus $748 from 17 others

What the payments were for

  • Food & beverage$2,15699%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,171 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban266$220,332
Trelegy ElliptaFluticasone/Umeclidin/Vilanter153$136,550
JardianceEmpagliflozin67$80,422
FarxigaDapagliflozin Propanediol81$75,219
OzempicSemaglutide53$60,476
MounjaroTirzepatide50$57,094
TrulicityDulaglutide25$29,039
JanuviaSitagliptin Phosphate24$22,923
InvokanaCanagliflozin14$22,813
MyrbetriqMirabegron38$21,444
XareltoRivaroxaban19$17,098
Atorvastatin Calcium720$11,128
Lantus SolostarInsulin Glargine,hum.Rec.Anlog78$10,055
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$8,782
Breo ElliptaFluticasone/Vilanterol16$8,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$272$220,332266 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$124$153,710183 claims
Lilly USA, LLCMounjaro, Trulicity$55$86,13375 claims
AstraZenecaFarxiga, Symbicort$189$81,719102 claims
Boehringer IngelheimJardiance$281$80,42267 claims
Novo NordiskOzempic$185$60,47653 claims
Johnson & JohnsonInvokana, Xarelto$50$39,91233 claims
MerckJanuvia$20$22,92324 claims
Astellas Pharma US IncMyrbetriq$73$21,44438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Gaylord

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →